Compare HRTG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | ERAS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 1.0B |
| IPO Year | 2014 | 2021 |
| Metric | HRTG | ERAS |
|---|---|---|
| Price | $24.63 | $12.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $32.50 | $5.78 |
| AVG Volume (30 Days) | 242.0K | ★ 5.9M |
| Earning Date | 03-10-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.61 | N/A |
| EPS | ★ 4.83 | N/A |
| Revenue | ★ $842,277,000.00 | N/A |
| Revenue This Year | $5.45 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | $5.14 | ★ N/A |
| Revenue Growth | ★ 6.12 | N/A |
| 52 Week Low | $9.89 | $1.01 |
| 52 Week High | $31.98 | $12.69 |
| Indicator | HRTG | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 74.50 |
| Support Level | $24.23 | $11.41 |
| Resistance Level | $25.87 | $12.69 |
| Average True Range (ATR) | 1.02 | 0.72 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 21.71 | 87.35 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.